Search

Your search keyword '"Mehnert, Janice"' showing total 12 results
Start Over Author "Mehnert, Janice" Journal cancer research
12 results on '"Mehnert, Janice"'

1. Abstract CT032: Trials in progress: a global phase 1/1b clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma

Author

Spira, Alexander, primary, Gambardella, Valentina, additional, Kato, Shumei, additional, Perez, Cesar Batista, additional, Mckean, Meredith, additional, Cao, Maria Gonzalez, additional, Kim, Richard, additional, Chen, Chris T, additional, Italiano, Antoine, additional, Cassier, Philippe, additional, Mehnert, Janice, additional, Chmielowski, Bartosz, additional, Lee, Gerri, additional, Severson, Paul, additional, Unger, Caro, additional, Guan, Xiaowei, additional, Williams, Richard, additional, and Long, Georgina, additional

Published
2023
Full Text
View/download PDF

2. Abstract CT139: Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study

Author

Silk, Ann W., primary, O'Day, Steven J., additional, Kaufman, Howard L., additional, Bryan, Jennifer, additional, Norrell, Jacqueline T., additional, Imbergamo, Casey, additional, Portal, Daniella, additional, Zambrano-Acosta, Edwin, additional, Palmeri, Marisa, additional, Fein, Seymour, additional, Wu, Cai, additional, Guerreiro, Leslie, additional, Medina, Daniel, additional, Bommareddy, Praveen K., additional, Zloza, Andrew, additional, Fox, Bernard A., additional, Ballesteros-Merino, Carmen, additional, Shafren, Darren, additional, Grose, Mark, additional, Vieth, Joshua A., additional, and Mehnert, Janice M., additional

Published
2021
Full Text
View/download PDF

3. Abstract CT013: SWOG S1320: Improved progression-free survival with continuous compared to intermittent dosing with dabrafenib and trametinib in patients with BRAF mutated melanoma

Author

Algazi, Alain, primary, Othus, Megan, additional, Daud, Adil, additional, Lo, Roger, additional, Mehnert, Janice, additional, Truong, Thach-Giao, additional, Conry, Robert, additional, Kendra, Kari, additional, Doolittle, Gary, additional, Clark, Joseph I., additional, Messino, Michael, additional, Moore, Dennis F., additional, Lao, Christopher, additional, Faller, Bryan A., additional, Govindarajan, Rangaswamy, additional, Harker-Murray, Amy, additional, Dreisbach, Luke, additional, Moon, James, additional, Grossman, Kenneth, additional, and Ribas, Antoni, additional

Published
2020
Full Text
View/download PDF

4. Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies

Author

Chung, Hyun Cheol, primary, Piha-Paul, Sarina A., additional, Lopez-Martin, Jose, additional, Schellens, Jan H.M., additional, Kao, Steven, additional, Miller, Wilson H., additional, Delord, Jean-Pierre, additional, Gao, Bo, additional, Planchard, David, additional, Gottfried, Maya, additional, Zer, Alona, additional, Jalal, Shadia I., additional, Penel, Nicolas, additional, Mehnert, Janice M., additional, Matos, Ignacio, additional, Bennouna, Jaafar, additional, Kim, Dong-Wan, additional, Xu, Lei, additional, Krishnan, Suba, additional, Norwood, Kevin, additional, and Ott, Patrick A., additional

Published
2019
Full Text
View/download PDF

5. Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer

Author

Krishnamurthy, Anuradha, primary, Dasari, Arvind, additional, Noonan, Anne M., additional, Mehnert, Janice M., additional, Lockhart, Albert C., additional, Leong, Stephen, additional, Capasso, Anna, additional, Stein, Mark N., additional, Sanoff, Hanna K., additional, Lee, James J., additional, Hansen, Aaron, additional, Malhotra, Usha, additional, Rippke, Sarah, additional, Gustafson, Daniel L., additional, Pitts, Todd M., additional, Ellison, Kim, additional, Davis, S. Lindsey, additional, Messersmith, Wells A., additional, Eckhardt, S. Gail, additional, and Lieu, Christopher H., additional

Published
2018
Full Text
View/download PDF

6. Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 ( C V A 21) and systemicp emb r olizumab ina dvanced melanoma patients: Interim results of the CAPRA clinical trial

Author

Silk, Ann W., primary, Kaufman, Howard, additional, Gabrail, Nashat, additional, Mehnert, Janice, additional, Bryan, Jennifer, additional, Norrell, Jacqueline, additional, Medina, Daniel, additional, Bommareddy, Praveen, additional, Shafren, Darren, additional, Grose, Mark, additional, and Zloza, Andrew, additional

Published
2017
Full Text
View/download PDF

9. Abstract 3513: Hydroxychoroquine (HCQ) modulates autophagy in melanoma: preliminary results of a phase 0 trial in patients with resectable melanoma.

Author

Mehnert, Janice M., primary, Xie, Xiaoqi, additional, Rajpal, Megha, additional, Dudek, Liesel, additional, Mehta, Monal, additional, Karantza, Vassiliki, additional, Gounder, Murugesan, additional, Aisner, Joseph, additional, Shih, Weichung, additional, Patel, Rajesh, additional, Chen, Chunxia, additional, Goydos, James, additional, Amaravadi, Ravi K., additional, and White, Eileen P., additional

Published
2013
Full Text
View/download PDF

11. Abstract 4717: Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies

Author

Moss, Rebecca A., primary, Bothos, John G., additional, Patel, Premal H., additional, Peterson, Amy C., additional, Eppler, Steve, additional, Bai, Shuang, additional, Nijem, Ihsan, additional, Desnoyers, Luc, additional, Kaur, Surinder, additional, Zha, Jiping, additional, Yu, Wei, additional, Simpson, Joe, additional, Ratain, Mark J., additional, Tan, Antoinette R., additional, Stein, Mark N., additional, Mehnert, Janice M., additional, and Salgia, Ravi, additional

Published
2011
Full Text
View/download PDF

12. Activation of the Glutamate Receptor GRM1 Enhances Angiogenic Signaling to Drive Melanoma Progression.

Author

Yu Wen, Jiadong Li, Koo, Jasmine, Seung-Shick Shin, Yong Lin, Byeong-Seon Jeong, Mehnert, Janice M., Chen, Suzie, Cohen-Sola, Karine A., and Goydos, James S.

Subjects
*GLUTAMATE receptors, *AMINO acid receptors, *VASCULAR endothelial growth factors, *MELANOMA, *NEUROENDOCRINE tumors
Abstract

Glutamate-triggered signal transduction is thought to contribute widely to cancer pathogenesis. In melanoma, overexpression of the metabotropic glutamate receptor (GRM)-1 occurs frequently and its ectopic expression in melanocytes is sufficient for neoplastic transformation. Clinical evaluation of the GRM1 signaling inhibitor riluzole in patients with advanced melanoma has demonstrated tumor regressions that are associated with a suppression of the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathways. Together, these results prompted us to investigate the downstream consequences of GRM1 signaling and its disruption in more detail. We found that melanoma cells with enhanced GRM1 expression generated larger tumors in vivo marked by more abundant blood vessels. Media conditioned by these cells in vitro contained relatively higher concentrations of interleukin-8 and VEGF due to GRM1-mediated activation of the AKT-mTOR-HIF1 pathway. In clinical specimens from patients receiving riluzole, we confirmed an inhibition of MAPK and PI3K/AKT activation in posttreatment as compared with pretreatment tumor specimens, which exhibited a decreased density of blood vessels. Together, our results demonstrate that GRM1 activation triggers proangiogenic signaling in melanoma, offering a mechanistic rationale to design treatment strategies for the most suitable combinatorial use of GRM1 inhibitors in patients. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results